Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for rivaroxaban ...

Indoco Remedies Ltd., a fully integrated, research-oriented pharmaceutical company, announced final approval of the company’s Abbreviated New Drug Application (ANDA) for rivaroxaban tablets USP, 2.5 ...

In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding ...

Perugia, Italy - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) have been ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BARCELONA -- ...

Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring ...

(HealthDay News) — Rivaroxaban is associated with reduced risk of recurrent events among patients with venous thromboembolism in equipoise for continued anticoagulation, according to a study published ...

A short IV bolus of a ‘decoy’ molecule almost immediately reverses rivaroxaban anticoagulation, according to a proof-of-concept study. The new agent relieves some concern about management of patients ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. • Rivaroxaban (COVIXABAN) is indicated for ...